HK1214765A1 - 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 - Google Patents

包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 Download PDF

Info

Publication number
HK1214765A1
HK1214765A1 HK16102742.9A HK16102742A HK1214765A1 HK 1214765 A1 HK1214765 A1 HK 1214765A1 HK 16102742 A HK16102742 A HK 16102742A HK 1214765 A1 HK1214765 A1 HK 1214765A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor
treatment
proliferative diseases
pharmaceutical combination
histone deacetylase
Prior art date
Application number
HK16102742.9A
Other languages
English (en)
Chinese (zh)
Inventor
John GALLAGHER Stuart
Hersey Peter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1214765A1 publication Critical patent/HK1214765A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16102742.9A 2012-11-08 2013-11-08 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途 HK1214765A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723925P 2012-11-08 2012-11-08
US201261723925P 2012-11-08
PCT/EP2013/073452 WO2014072493A1 (en) 2012-11-08 2013-11-08 Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
HK1214765A1 true HK1214765A1 (zh) 2016-08-05

Family

ID=49552384

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102742.9A HK1214765A1 (zh) 2012-11-08 2013-11-08 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途

Country Status (11)

Country Link
US (1) US20150283136A1 (enExample)
EP (1) EP2916834A1 (enExample)
JP (1) JP2015536964A (enExample)
CN (1) CN104994850A (enExample)
AU (1) AU2013343425A1 (enExample)
BR (1) BR112015010477A2 (enExample)
CA (1) CA2890663A1 (enExample)
HK (1) HK1214765A1 (enExample)
RU (1) RU2015121367A (enExample)
UA (1) UA115151C2 (enExample)
WO (1) WO2014072493A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
RS58048B1 (sr) 2011-11-23 2019-02-28 Array Biopharma Inc Farmaceutske formulacije
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017019664A1 (en) * 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US10864179B2 (en) * 2015-10-01 2020-12-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3571200B8 (en) 2017-01-17 2022-08-03 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
DK2688572T3 (en) * 2011-03-21 2017-06-12 Valcuria Ab PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
NZ618367A (en) * 2011-06-14 2016-01-29 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Also Published As

Publication number Publication date
JP2015536964A (ja) 2015-12-24
CN104994850A (zh) 2015-10-21
WO2014072493A1 (en) 2014-05-15
EP2916834A1 (en) 2015-09-16
US20150283136A1 (en) 2015-10-08
AU2013343425A1 (en) 2015-06-11
UA115151C2 (uk) 2017-09-25
RU2015121367A (ru) 2017-01-10
CA2890663A1 (en) 2014-05-15
BR112015010477A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
HK1214765A1 (zh) 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
IN2015DN00376A (enExample)
IN2015DN00450A (enExample)
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EP2916827A4 (en) METHOD AND DEVICES FOR THE TREATMENT OF EYE DISEASES IN HUMAN PATIENTS
PH12016501015A1 (en) Combinations of histone deacetylase inhibitors and immunomodulatory drugs
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
NZ700872A (en) Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
UA115250C2 (uk) Фармацевтичні комбінації
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2013177067A3 (en) Herbal composition for treatment of gastrointestinal inflammatory diseases and method to prepare and use thereof
JP2014526564A5 (enExample)
WO2016049580A3 (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
EP2928460A4 (en) METHOD FOR PREVENTING AND TREATING FLAMMABLE SKIN DISEASES
IL284298A (en) Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases
EP2957569A4 (en) (ARGO) N-ANGIOTENSIN (1-7) PEPTIDE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ILLNESSES
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment